TY - JOUR
T1 - Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis
AU - Laster, Marciana
AU - Soohoo, Melissa
AU - Streja, Elani
AU - Elashoff, Robert
AU - Jernigan, Stephanie
AU - Langman, Craig B.
AU - Norris, Keith C.
AU - Salusky, Isidro B.
AU - Kalantar-Zadeh, Kamyar
N1 - Funding Information:
Funding source The work in this manuscript has been performed with the support of the National Institute of Diabetes, Digestive and Kidney Disease of the National Institute of Health research grants R01-DK95668 (KKZ), K24-DK091419 (KKZ), R01-DK078106 (KKZ), and T32-DK104687 (ML). KKZ is supported by philanthropic grants from Mr. Harold Simmons, Mr. Louis Chang, Mr. Joseph Lee, and AVEO. KN is supported by NIH grants UL1TR000124 and P30AG021684.
Funding Information:
We thank DaVita Clinical Research (DCR) for providing statistically de-identified data used in this study. Institutional Review Board approval was obtained from the University of California, Irvine. Given the lack of patient identifiable information and the lack of patient burden, consent was exempted in this study. KKZ has received honoraria and/or support from Abbott, Abbvie, Alexion, Amgen, American Society of Nephrology, Astra-Zeneca, AVEO, Chugai, DaVita, Fresenius, Genetech, Haymarket Media, Hospira, Kabi, Keryx, National Institutes of Health, National Kidney Foundation, Relypsa, Resverlogix, Sanofi, Shire, Vifor, and ZS-Pharma. Dr. Isidro B. Salusky is a consultant for Keryx and has received honoraria from Amgen, Abbvie, and OPKO. Dr. Craig B Langman is a consultant for Alexion Pharma Inc., Dicerna Pharma Inc., and Janssen Pharma Inc.
Publisher Copyright:
© 2018, IPNA.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Studies in healthy pediatric populations and adults treated with dialysis demonstrate higher parathyroid hormone (PTH) and lower 25-hydroxyvitamin D levels in African-Americans. Despite these findings, African-Americans on dialysis demonstrate greater bone strength and a decreased risk of fracture compared to the Caucasian dialysis population. The presence of such differences in children and young adult dialysis patients is unknown. Methods: Differences in the markers of mineral and bone metabolism (MBM) were assessed in 661 incident dialysis patients (aged 1 month to < 21 years). Racial-ethnic differences in PTH, calcium, phosphate, and total alkaline phosphatase (AP) activity were analyzed over the first year of dialysis using multivariate linear mixed models. Results: African-American race predicted 23% higher serum PTH (95% CI, 4.7–41.3%) when compared to Caucasian patients, while Hispanic ethnicity predicted 17.5% higher PTH (95% CI, 2.3–38%). Upon gender stratification, the differences in PTH were magnified in African-American and Hispanic females: 38% (95% CI, 14.8–69.8%) and 28.8% (95% CI, 4.7–54.9%) higher PTH compared to Caucasian females. Despite higher PTH values, African-American females persistently demonstrated up to 10.9% lower serum AP activity (95% CI, − 20.6–− 0.7%). Conclusions: There are racial-ethnic differences in the markers of MBM. Higher PTH is seen in African-American and Hispanic children and young adults on dialysis with a magnification of this difference amongst the female population. There is a need to consider how factors like race, ethnicity, and gender impact the goal-targeted treatment of MBM disorders.
AB - Background: Studies in healthy pediatric populations and adults treated with dialysis demonstrate higher parathyroid hormone (PTH) and lower 25-hydroxyvitamin D levels in African-Americans. Despite these findings, African-Americans on dialysis demonstrate greater bone strength and a decreased risk of fracture compared to the Caucasian dialysis population. The presence of such differences in children and young adult dialysis patients is unknown. Methods: Differences in the markers of mineral and bone metabolism (MBM) were assessed in 661 incident dialysis patients (aged 1 month to < 21 years). Racial-ethnic differences in PTH, calcium, phosphate, and total alkaline phosphatase (AP) activity were analyzed over the first year of dialysis using multivariate linear mixed models. Results: African-American race predicted 23% higher serum PTH (95% CI, 4.7–41.3%) when compared to Caucasian patients, while Hispanic ethnicity predicted 17.5% higher PTH (95% CI, 2.3–38%). Upon gender stratification, the differences in PTH were magnified in African-American and Hispanic females: 38% (95% CI, 14.8–69.8%) and 28.8% (95% CI, 4.7–54.9%) higher PTH compared to Caucasian females. Despite higher PTH values, African-American females persistently demonstrated up to 10.9% lower serum AP activity (95% CI, − 20.6–− 0.7%). Conclusions: There are racial-ethnic differences in the markers of MBM. Higher PTH is seen in African-American and Hispanic children and young adults on dialysis with a magnification of this difference amongst the female population. There is a need to consider how factors like race, ethnicity, and gender impact the goal-targeted treatment of MBM disorders.
KW - Biochemical markers of bone turnover
KW - Children
KW - Chronic kidney disease-mineral bone disease
KW - Dialysis
KW - Parathyroid-related disorders
UR - http://www.scopus.com/inward/record.url?scp=85054196021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054196021&partnerID=8YFLogxK
U2 - 10.1007/s00467-018-4048-6
DO - 10.1007/s00467-018-4048-6
M3 - Article
C2 - 30267239
AN - SCOPUS:85054196021
SN - 0931-041X
VL - 34
SP - 107
EP - 115
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 1
ER -